Har kigget lidt på tallene for 2024, hvad USA har sat af til Bavarian's produkter. Både Ebola, MPOX, Rabies og Smallpox, bliver fremhævet.
Lige hvor mange penge der bliver brugt på hver vaccine i 2024, bliver der ikke skrevet, men at de vil opbygge et stort lager for at beskytte USA's befolkning.
Det er ret store beløb vi taler om, så mon ikke der er nogle kontrakter på vej til Bavarian?
BUILDING A HEALTHY AMERICA FY 2024 President's Budget for HHS
Pandemic Preparedness The FY 2024 budget includes $20 billion in mandatory funding across HHS to support President's plan to transform U.S. capabilities to prepare for and respond rapidly and effectively to future pandemics and other high consequence biological threats. Of this total, $6.1 billion will be allocated to CDC to modernize and build laboratory capacity, strengthen public health data systems; enhance domestic and global disease surveillance, biosafety, and biosecurity efforts; and support capabilities for monitoring and evaluating vaccine and medical countermeasure safety and effectiveness.
PREPARING FOR FUTURE PUBLIC HEALTH THREATS The federal response to recent public health threats, including the COVID-19 pandemic, has highlighted the importance of preparedness for future public health threats. The budget includes $20 billion in mandatory funding, available over 5 years, across the Administration for Strategic Preparedness and Response (ASPR), Centers for Disease Control and Prevention (CDC), NIH, and the Food and Drug Administration (FDA) to support the President's plan to transform the nation's capabilities to prepare for and respond rapidly and effectively to future pandemics and other biological threats.
Emerging Infectious Diseases With an additional $40 million above FY 2023 enacted, the budget will expand CDC's core emerging infectious disease work. This includes improving laboratory capabilities at the federal, state, and local levels that are necessary for response to outbreaks for a range of critical and emerging pathogens, including mpox, Ebola, anthrax, and rabies.
Project BioShield Under the Project BioShield program, BARDA supports late-stage development and procures medical countermeasures that can be used during a public health emergency and that are ready to be delivered to the Strategic
National Stockpile. These medical countermeasures include vaccines, therapeutics, and other countermeasures that treat anthrax, botulism, smallpox, radiation, thermal burns, and other threats. The budget provides $830 million for Project BioShield in FY 2024, which is $10 million above the FY 2023 President's Budget. With this funding, Project BioShield will develop and procure: • Up to three new antibiotics to bolster preparedness against drug-resistant pathogens; • Products that treat burns, blasts, and exposure to nerve agents; • A therapeutic that could potentially treat Ebola Sudan or other ebolaviruses; and • Smallpox antivirals and a smallpox vaccine that can be administered to populations for which a live smallpox vaccine is not recommended.
Strategic National Stockpile The Strategic National Stockpile stores, maintains, and rapidly deploys lifesaving medical supplies, medicines, and devices to states, tribal populations, territories, and metropolitan areas during public health emergencies. ASPR's robust medical logistics capability can move medical personnel, equipment, and supplies across the nation within hours; this supports timely delivery of medical countermeasures during an emergency response. The FY 2024 budget funds the Stockpile at $995 million, an increase of $30 million above FY 2023 enacted. These funds will ensure the Stockpile's assets are available and ready to protect America from 21st century health threats in FY 2024. The increased funding will be used to sustain current product lines and to procure targeted countermeasures previously supported by BARDA that lack a significant commercial market.
Lige hvor mange penge der bliver brugt på hver vaccine i 2024, bliver der ikke skrevet, men at de vil opbygge et stort lager for at beskytte USA's befolkning.
Det er ret store beløb vi taler om, så mon ikke der er nogle kontrakter på vej til Bavarian?
BUILDING A HEALTHY AMERICA FY 2024 President's Budget for HHS
Pandemic Preparedness The FY 2024 budget includes $20 billion in mandatory funding across HHS to support President's plan to transform U.S. capabilities to prepare for and respond rapidly and effectively to future pandemics and other high consequence biological threats. Of this total, $6.1 billion will be allocated to CDC to modernize and build laboratory capacity, strengthen public health data systems; enhance domestic and global disease surveillance, biosafety, and biosecurity efforts; and support capabilities for monitoring and evaluating vaccine and medical countermeasure safety and effectiveness.
PREPARING FOR FUTURE PUBLIC HEALTH THREATS The federal response to recent public health threats, including the COVID-19 pandemic, has highlighted the importance of preparedness for future public health threats. The budget includes $20 billion in mandatory funding, available over 5 years, across the Administration for Strategic Preparedness and Response (ASPR), Centers for Disease Control and Prevention (CDC), NIH, and the Food and Drug Administration (FDA) to support the President's plan to transform the nation's capabilities to prepare for and respond rapidly and effectively to future pandemics and other biological threats.
Emerging Infectious Diseases With an additional $40 million above FY 2023 enacted, the budget will expand CDC's core emerging infectious disease work. This includes improving laboratory capabilities at the federal, state, and local levels that are necessary for response to outbreaks for a range of critical and emerging pathogens, including mpox, Ebola, anthrax, and rabies.
Project BioShield Under the Project BioShield program, BARDA supports late-stage development and procures medical countermeasures that can be used during a public health emergency and that are ready to be delivered to the Strategic
National Stockpile. These medical countermeasures include vaccines, therapeutics, and other countermeasures that treat anthrax, botulism, smallpox, radiation, thermal burns, and other threats. The budget provides $830 million for Project BioShield in FY 2024, which is $10 million above the FY 2023 President's Budget. With this funding, Project BioShield will develop and procure: • Up to three new antibiotics to bolster preparedness against drug-resistant pathogens; • Products that treat burns, blasts, and exposure to nerve agents; • A therapeutic that could potentially treat Ebola Sudan or other ebolaviruses; and • Smallpox antivirals and a smallpox vaccine that can be administered to populations for which a live smallpox vaccine is not recommended.
Strategic National Stockpile The Strategic National Stockpile stores, maintains, and rapidly deploys lifesaving medical supplies, medicines, and devices to states, tribal populations, territories, and metropolitan areas during public health emergencies. ASPR's robust medical logistics capability can move medical personnel, equipment, and supplies across the nation within hours; this supports timely delivery of medical countermeasures during an emergency response. The FY 2024 budget funds the Stockpile at $995 million, an increase of $30 million above FY 2023 enacted. These funds will ensure the Stockpile's assets are available and ready to protect America from 21st century health threats in FY 2024. The increased funding will be used to sustain current product lines and to procure targeted countermeasures previously supported by BARDA that lack a significant commercial market.
